NHH9 Conference

The 9th edition of the New Horizons in Haematology Conference (NHH9) took place on the 26th of September 2014.A�The NHH9 scientific panel was connected from the central studio with 6 cities, expanding the international reach to as far as Japan.

Over 90% of attendees found the conference extremely engaging. The panel discussions were highly rated with debates consideringA�whether the latest genetic discoveries, such as the CALR mutation, would have an impact in clinical practice in Myeloproliferative Neoplasms (MPNs).

NHH9 CONTENT

NHH9a?�a?�a?�a�?a?�a??a??a??a?Ya????�e��a?�a�?a?�a��a?�a��e�?a��a?�a??a�?a?�a?�a??a??a�?a��a�?a??a??a�?

Will theA�CALR mutation be the new JAK2?

 

 

Professor Stefan Constantinescu:

Biography/Abstract/Reference ListA� A� A�Presentation

Professor Jean-Jacques Kiladjian:

Biography/Abstract/Reference ListA� A� A�Presentation

Will the latest genetic discoveries have an impact on clinical management in ET and MF?

 

 

Professor Alessandro Vannucchi:

Biography/Abstract/Reference ListA� A� A�Presentation

Professor Ruben A. Mesa:

Biography/Abstract/Reference ListA� A� A�PresentationA� A� A�Supplementary Definitions

NHH9 CONFERENCE

The agenda of the NHH9 Conference provides an overview of the conference topics and highlights all of the participants involved in this interactive event. For further details see below.

 

LATEST GENETIC ADVANCES
IN MPNs:
WHAT ARE
THE CLINICAL IMPLICATIONS?


Will the CALR mutation be the new JAK2?

Prof. Stefan Constantinescu

UniversitA� Catholique de Louvrain, Brussels, Belgium

Prof. Jean-Jacques Kiladjian

Clinical Investigation Centre, Saint-Louis Hospital, Paris, France


Will the latest genetic discoveries have an impact on clinical
management in ET and MF?

Prof. Alessandro Vannucchi

Department of Experimental and Clinical Medicine, University of Florence, Italy

Prof. Ruben A. Mesa

Division of Haematology/Oncology, Mayo Clinic, Arizona, US


Moderated by Dr Sarah Jarvis